No Data
No Data
OptimizeRx (NASDAQ:OPRX) Shareholders Have Endured a 83% Loss From Investing in the Stock Three Years Ago
Critical Insights From OptimizeRx Analyst Ratings: What You Need To Know
JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $16 Price Target
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $16
JMP Securities analyst Constantine Davides maintains $OptimizeRx(OPRX.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 23.6%
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
OptimizeRx | 10-Q: Quarterly report